ArticleBMJ open2026

Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10).

Yukinori Ozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.